论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
血小板-肿瘤细胞杂交膜修饰纳米粒增强胶质瘤治疗效果
Authors Wu L, Li Q, Deng J, Shen J, Xu W, Yang W, Chen B, Du Y , Zhang W, Ge F, Lei S, Li K, Wang Z
Received 8 August 2021
Accepted for publication 5 December 2021
Published 29 December 2021 Volume 2021:16 Pages 8433—8446
DOI https://doi.org/10.2147/IJN.S333279
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Editor who approved publication: Prof. Dr. Anderson Oliveira Lobo
Purpose: Cell membrane-camouflaged nanoparticles (NPs) are drawing increasing attention because their surfaces acquire some characteristics of the cell membranes, making them a unique class of biomimetic materials for diverse applications. Modification of cell membrane or combination of different types of membranes can enhance their functionality.
Methods: We prepared platelet and tumor cell membrane camouflaged β-mangostin-loaded NPs, which were synthesized with platelet–C6 hybrid biomimetic coating, poly(lactic-co-glycolic acid), and β-mangostin (β-PCNPs). Then, we evaluated their targeting ability and anticancer activity against glioma in vitro and in vivo.
Results: Biomimetic coating enhanced active drug targeting and immune escape properties of nanocarrier in C6 and THP-1 cells, respectively, which improved their cytotoxicity. β-PCNPs were characterized to study the inherent properties of both source cells. Compared with bare β-NPs, β-PCNPs exhibited high tumor-targeting capability and induced apoptosis of C6 cells in vitro. Similarly, intravenous administration of drug through β-PCNPs resulted in enhanced tumor-targeting and exhibited excellent rate of inhibition of glioma tumor growth in mice. Moreover, the blood circulation time of drug in mice in the β-PCNP group was markedly prolonged and these mice exhibited better outcome than those in the β-NP group.
Conclusion: These results provide a new strategy of utilizing PCNPs as carriers for drug delivery, which improves the targeting efficiency and therapeutic efficacy of chemotherapeutic agents for glioma therapy.
Keywords: glioma, hybrid membrane, biomimetic, β-mangostin, targeted delivery, anticancer